Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&D Expense (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2021	Mar. 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development	$ 20,000	$ 30	$ 2,805
Seralutinib
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development		0	0
GB004
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development		0	0
GB1275
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development		0	0
Other preclinical programs
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development		$ 30	$ 2,805